The best weight loss injections for women are the three FDA-approved options: tirzepatide (Zepbound), semaglutide (Wegovy), and liraglutide (Saxenda), all approved for adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition. Tirzepatide and semaglutide are the preferred agents because they produce the most weight loss, and women may experience slightly greater results than men with these medications. Before starting, there are women-specific points worth understanding, especially around fertility, contraception, and preserving muscle.
This guide compares the approved injections and their safety profile, and focuses on what women in particular should know before starting. Everything here is educational, results vary, and any decision should be made with a licensed healthcare provider.
Three injectable medications are FDA-approved for chronic weight management, and they are the same for women as for men, though the considerations around starting them can differ. The 2025 American College of Cardiology consensus statement identifies semaglutide and tirzepatide as the preferred agents because of their superior efficacy. The three compare as follows.
| Medication | Type | Dosing | Avg. weight loss vs. placebo |
| Tirzepatide (Zepbound) | Dual GLP-1/GIP | Weekly, titrated to 5 to 15 mg | 15 to 21% (vs. 3.1%) |
| Semaglutide (Wegovy) | GLP-1 | Weekly, titrated to 2.4 mg | 14.9% (vs. 2.4%) |
| Liraglutide (Saxenda) | GLP-1 | Daily, titrated to 3.0 mg | 8.0% (vs. 2.6%) |
In head-to-head research, semaglutide produced about 15.8 percent weight loss versus 6.4 percent for liraglutide over 68 weeks, and tirzepatide produced about 20.2 percent versus 13.7 percent for semaglutide over 72 weeks. Weight reduction was roughly 6 percentage points greater in women than men in both groups of that trial, and real-world data also show tirzepatide ahead of semaglutide at 12 months. These are clinical trial averages, and individual results vary.
There are reasons women may respond slightly more strongly. Differences in body composition, hormones, and how these medications are distributed and metabolized are thought to play a role, though the practical point is simply that the strong results seen in trials apply well to women. The flip side is that the same biology means side effects and dosing still need to be individualized; a smaller person, for example, may reach an effective response at a lower dose. None of this changes which medications are most effective, but it reinforces that the dose and pace should be tailored to the person.
Wondering which weight loss injection is right for you?
→ See if you qualify
Gastrointestinal side effects are the most common across all three injections, including nausea (about 25 to 44 percent), diarrhea (19 to 30 percent), vomiting (8 to 24 percent), and constipation (17 to 24 percent). They tend to occur during dose increases and improve with slow titration. Treatment was stopped because of side effects in roughly 4 to 7 percent of trial participants.
All three carry a contraindication for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, and caution is warranted regarding pancreatitis, gallbladder disease, and kidney function. One side effect that deserves special attention is the loss of lean muscle: roughly 30 percent of the weight lost on GLP-1-based therapy can be lean mass. Because muscle and bone matter for long-term health, this is something to actively protect, not ignore.
Because a meaningful share of weight lost is lean mass, and because one trial found that GLP-1 therapy alone decreased bone mineral density while combining it with exercise preserved bone, current joint advisory guidelines are specific about how to use these medications well. They recommend pairing a GLP-1 injection with structured resistance training at least three times a week and at least 150 minutes of moderate-intensity aerobic exercise weekly.
This matters for everyone but is particularly relevant for women, who are already at higher lifetime risk of osteoporosis. In practical terms, the injection works best as part of a plan that includes strength training and adequate protein, not on its own. A medically supervised program can build in this support so the weight you lose is mostly fat while your muscle and bone are protected.
Want a plan that protects muscle while you lose fat? A licensed provider can help.
→ Take the 2-minute eligibility quiz
Beyond the general safety profile, there are considerations that apply specifically to women, especially those of reproductive age.
Fertility and PCOS. GLP-1 receptor agonists may improve ovulation and menstrual regularity, particularly in women with polycystic ovary syndrome (PCOS). That can be a welcome benefit, but it also means fertility may increase, raising the chance of both intended and unintended pregnancy.
Pregnancy and contraception. The Endocrine Society recommends discontinuing GLP-1 receptor agonists before pregnancy, with semaglutide stopped at least two months beforehand, based on animal data linking marked maternal weight loss to fetal abnormalities, though a consistent teratogenic signal has not been shown in humans. Effective contraception should be used while on therapy. Importantly, because these medications slow stomach emptying, they may variably affect the absorption of oral contraceptives, so discuss birth control with your provider.
Weight regain after stopping. Significant weight regain is common after discontinuation, with about 11.6 percent regained over the year after stopping in the STEP trials. These are chronic-use medications, which is an important expectation to set, particularly if you plan to pause for pregnancy.
A note on Qsymia. Although it is an oral medication rather than an injection, phentermine-topiramate (Qsymia) is a known teratogen associated with oral clefts and requires a negative pregnancy test before starting and monthly afterward in women who could become pregnant. It is worth knowing if you are weighing oral alternatives.
It is easy to get confused by the terms used online. A slim shot injection is an informal marketing phrase, not a specific approved product, and it is sometimes used to refer to legitimate GLP-1 weight loss injections and sometimes to vitamin or lipotropic shots that have no proven weight-loss benefit. If a slim shot is a GLP-1 medication prescribed and monitored by a clinician, it has real evidence behind it; if it is a B12 or lipotropic blend sold as a metabolism booster, it does not.
Similarly, fat reducing injections such as deoxycholic acid (Kybella) are a different category entirely. Kybella is FDA-approved only to reduce a small pocket of fat under the chin for cosmetic reasons, not for overall weight loss. It will not help you lose body weight. The reliable, evidence-based injectable route to meaningful weight loss for women is the FDA-approved GLP-1 and dual agonist medications, used under medical supervision. When in doubt, ask a provider exactly what is in any shot you are offered.
The AGA guideline suggests semaglutide 2.4 mg may be prioritized for most patients given the size of its benefit, while the ACC notes that in practice, insurance coverage, availability, and affordability often dictate which agent is used. Your other health conditions also guide the choice: the GLP-1 medications offer dual benefits if you have type 2 diabetes, and semaglutide has demonstrated cardiovascular and kidney benefits.
For women, the best choice balances effectiveness with your personal circumstances, including whether you may want to become pregnant, your risk factors, and your ability to access and stay on a given medication. Because all of these are prescription-only and carry specific considerations, the right starting point is a medical evaluation. Talk to a healthcare provider to find the option that fits your health, goals, and life stage.
One expectation to set: these injections work best as part of a broader plan, not as a standalone fix. The trial results were achieved alongside changes to diet and activity, and the lean-mass and bone considerations make strength training and adequate protein genuinely important rather than optional extras. Thinking of the injection as the centerpiece of a comprehensive, medically supervised approach, rather than a shortcut, is what tends to produce the best and most durable results for women over the long term.
See whether a weight loss injection could be right for you. It takes about two minutes.
→ Check your eligibility
What is the best weight loss injection for women?
Tirzepatide (Zepbound) and semaglutide (Wegovy) are the most effective FDA-approved injections and are the preferred agents, with liraglutide (Saxenda) as a third option. Women may lose slightly more than men. The best choice depends on your health and is a decision for a provider.
Do weight loss injections affect fertility or birth control?
They can. GLP-1 medications may improve ovulation, especially in PCOS, which can increase fertility, and they may affect how well oral contraceptives are absorbed. Use effective contraception and discuss birth control with your provider before starting.
Can I use weight loss injections if I want to get pregnant?
These medications should be stopped before pregnancy, with semaglutide discontinued at least two months beforehand. If you are planning a pregnancy, talk to your provider about timing and alternatives.
How do I keep from losing muscle on these injections?
Because around 30 percent of weight lost can be lean mass, guidelines recommend resistance training at least three times a week, at least 150 minutes of weekly aerobic exercise, and adequate protein. A supervised program can build this in.
Are slim shots and fat-burning injections the same as these?
Not necessarily. Slim shot is a marketing term that may or may not refer to a real GLP-1 medication, and fat reducing injections like Kybella only treat a small cosmetic area, not body weight. Ask a provider exactly what any shot contains.
Learn more: FDD Weight Loss Program | Eligibility quiz
